Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children

NCT00129766 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT00129766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00129766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children
Lead sponsor
MedImmune LLC
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2004
Completion date
May 31, 2006
Enrollment
6,635 (actual)
Sites
344

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus infections